Vigilance
This article was originally published in SRA
Executive Summary
Canada requires disclosure of DEHP and bisphenol A in medical devices
You may also be interested in...
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Coherus Aiming For More Than 10% Slice Of US Adalimumab Market
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.
Executives On The Move: PYC Therapeutics Gets Chief Development Officer, New Chief Commercial Officer At Everest Medicines
New Directors Join Ambrx, Synedgen and Cogent Biosciences.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: